Highlights from the Report

The HPV vaccines market was estimated at USD 5.6 billion in 2021 and is likely to grow at a CAGR of 16.1% during 2022-2028 to reach USD 15.94 billion in 2028.

What is human papillomavirus (HPV)?

Human papillomavirus (HPV) infection is one of the most common sexually transmitted infections which is caused by HPV-related cancers, such as genital and cervical cancers. HPV infection vaccines are primarily used to prevent genital warts, cervical cancer, anal cancer, and vaginal cancer. Three commercially available HPV prevention vaccines, such as Gardasil 9 and Gardasil by Merck and Cervarix developed by GSK Plc, are known to be highly effective in preventing HPV infection and genital precancerous lesions.

COVID-19 IMPACT

The outbreak of the COVID-19 virus had a devastating impact on the HPV vaccine industry. The healthcare industry is currently facing major challenges as it is unable to provide proper medical facilities to cater to the ever-growing coronavirus patient pool. With the stringent imposition of lockdown and social distance regulations, there were limited check-ups of women suffering from sexually transmitted diseases. During the pandemic period in 2020, around 342,000 women lost their lives due to cervical cancer. Thus, a poor healthcare system due to limited medical professionals and funding affected the market growth.

The report comprises an analytical representation of the HPV Vaccines Market size along with current trends, challenges, and future estimations to depict imminent investment pockets. To understand the profitable trends and gain a stronger foothold, the report also helps the users with key information related to growth drivers, restraints, and opportunities in the market. The current HPV Vaccines Market forecast is quantitatively analyzed from a particular time period of 5 years to benchmark the financial competency. The user will also get detailed info about the market trends and share of key vendors.

This report studies the HPV Vaccines Market and has segmented the market in few ways, keeping in mind the interest of all the stakeholders across the value chain. Following are the ways in which the market is segmented.

By type, the HPV vaccines market has been bifurcated into bivalent, polyvalent.

  • Under these, the polyvalent segment accounted for the highest market share in 2021 and is projected to grow at a moderate CAGR in the coming years.
  • This is mainly attributed to their low cost and performance efficiency and that they are highly popular, especially in the developing countries of Asia Pacific, thus bolstering the segment growth.

By region, the North American market witnessed the highest market share in 2021 and is estimated to register at a considerable CAGR during the review period. This is mainly attributed to the strong presence of well-established healthcare facilities, along with the ease in the availability of necessary resources. Moreover, people are aware of the presence of vaccines and related therapeutic procedures, thus augmenting the for vaccination and treatment, further boosting regional growth.

The following are the key players in the HPV Vaccines Market:

  • Lumetrics (The U.S),
  • Marco (The U.S),
  • Voptica (Spain),
  • AMICO GROUP (UAE),
  • NIDEK (Japan),
  • Hanson Instruments (UK),
  • Alcon (Switzerland), Carl Zeiss (Germany),
  • Essilor (France), and Johnson & Johnson Visioncare Inc. (US).

About Stratview Research-

Stratview Research is a global market intelligence firm having a strong experienced team of industry veterans and research analysts. Stratview Research has been serving multiple clients across a wide array of industries. The services cover a broad spectrum of industries including but not limited to Energy Chemicals, Advanced Materials, Automotive, and Aerospace. At Stratview, we believe in building long term relations with our clients.

Connect with the team –

Call @:  +1-313-307-4176

Mail @:  [email protected]